
|Articles|June 1, 2004
- Volume 0 0
dual path
Advertisement
Articles in this issue
over 21 years ago
Examover 21 years ago
Managed Care Commentary:MCOs face new challengesover 21 years ago
Phytosterols may play role in atherosclerosisover 21 years ago
Dual pathway inhibition: Attacking cholesterol on two frontsover 21 years ago
Future Goals, Targets, and Treatments of DyslipidemiaNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
4
A Defining Moment for Health System Pharmacy: Advancing Competency, Policy, and Patient Need in 2026
5

























